<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681691</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00049740</org_study_id>
    <secondary_id>R21AG054955</secondary_id>
    <nct_id>NCT03681691</nct_id>
  </id_info>
  <brief_title>The Interaction Between Diabetes and Estradiol on Human Brain Metabolism in Postmenopausal Women</brief_title>
  <acronym>E2T2D</acronym>
  <official_title>The Interaction Between Diabetes and Estradiol on Human Brain Metabolism in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to test whether type 2 diabetes interacts with estradiol on&#xD;
      brain metabolism in vivo in humans. This will be accomplished by imaging brain metabolism&#xD;
      using positron emission tomography before and after short-term administration of transdermal&#xD;
      17β-estradiol in 10 postmenopausal women with diabetes and 10 non-diabetic postmenopausal&#xD;
      women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiological studies suggest there may be an interaction between type 2 diabetes and&#xD;
      estrogen in postmenopausal women, such that diabetes may interact with estrogen levels over&#xD;
      time to increase risk for dementia. The mechanism for this effect is now known. However,&#xD;
      animal research suggests that it may occur through estrogen's effects on cellular metabolism&#xD;
      of glucose and ketone bodies. The primary aim of this study is to test whether type 2&#xD;
      diabetes interacts with estradiol on brain metabolism in vivo in humans. This will be&#xD;
      accomplished by imaging brain metabolism using positron emission tomography before and after&#xD;
      short-term administration of transdermal 17β-estradiol in 10 postmenopausal women with&#xD;
      diabetes and 10 non-diabetic postmenopausal women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Actual">July 19, 2021</completion_date>
  <primary_completion_date type="Actual">July 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Primary Objective: The primary objective is to determine whether the effects of glucose and ketone body uptake to the brain in response to 8-week administration of transdermal 17β-estradiol differ in postmenopausal women with and without type 2 diabetes.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in uptake of glucose and ketone bodies in whole brain and Alzheimer's disease-related regions of interest.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Brain metabolism will be measured using PET tracers to examine brain glucose uptake (FDG PET) and ketone body (acetoacetate) uptake (AcAc). PET imaging data are co-registered to T1 structural MRI data to conduct region-of-interest based analyses. Absolute global and regional uptake of FDG and AcAc tracers will be quantified, as well as uptake of AcAc relative to FDG to find potential regions of compensatory ketone use</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in short-term memory and executive function composite scores.</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>A battery of cognitive tasks will be administered before and after estrogen administration. Composite z-scores will be calculated by calculating a z-score for each cognitive task and summing z-scores from -5 (low) to 5 (high) for the tasks designated as short-term memory and executive function.Higher scores denotes better outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Type 2</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Post menopausal women with diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women with type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post menopausal women without diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women without type 2 diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol patch</intervention_name>
    <description>transdermal 17β-estradiol patch</description>
    <arm_group_label>Post menopausal women with diabetes</arm_group_label>
    <arm_group_label>Post menopausal women without diabetes</arm_group_label>
    <other_name>Climara patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing to provide written informed consent&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Female, postmenopausal, aged 60-80&#xD;
&#xD;
          4. Normal results on recommended healthcare screenings (e.g., mammogram, pap smear,&#xD;
             colonoscopy)&#xD;
&#xD;
          5. BMI 20-35 kg/m2&#xD;
&#xD;
          6. No evidence of dementia or mild cognitive impairment (MoCA score &gt;25)&#xD;
&#xD;
          7. Able to access reliable transportation to study and intervention visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of hormone replacement therapy within the past 3 months&#xD;
&#xD;
          2. History of renal, heart, liver, or neurological disease; head injury with loss of&#xD;
             consciousness in the past 5 years; chronic pain, anxiety or depression&#xD;
&#xD;
          3. Presence of medical conditions that might contraindicate estrogen use (e.g.,&#xD;
             unexplained vaginal bleeding, history of reproductive tissue cancer, thrombosis)&#xD;
&#xD;
          4. Currently taking insulin, metformin, or any other drug or medication judged by the&#xD;
             study physician to affect safety or research outcomes of interest&#xD;
&#xD;
          5. Involved in another research study&#xD;
&#xD;
          6. Contraindications for MRI or PET scanning&#xD;
&#xD;
          7. Current smoker&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Hugenschmidt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>women's health</keyword>
  <keyword>estradiol</keyword>
  <keyword>postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided at the present time.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 19, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT03681691/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

